ReviewDrugs2009
Atazanavir: a review of its use in the management of HIV-1 infection.
Review in Drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 100 citations in OpenAlex.
- Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.Clinical drug investigation · 2014Trial
- Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.Antimicrobial agents and chemotherapy · 2013Trial
- Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment.Drug metabolism and disposition: the biological fate of chemicals · 2011Trial
- Deep learning in the discovery of antiviral peptides and peptidomimetics: databases and prediction tools.Molecular diversity · 2025Review
- Harnessing Antiviral Peptides: From Molecular Mechanisms to Clinical Translation.Current research in pharmacology and drug discovery · 2025Review
- New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs.Viruses · 2024Review
- Antiretroviral action of Rosemary oil-based atazanavir formulation and the role of self-nanoemulsifying drug delivery system in the management of HIV-1 infection.Drug delivery and translational research · 2024Article
- Article
- A Review of the Lidocaine in the Perioperative Period.Journal of personalized medicine · 2023Review
- Recent Patents and FDA-Approved Drugs Based on Antiviral Peptides and Other Peptide-Related Antivirals.International journal of peptide research and therapeutics · 2023Review
- Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality.Pulmonary pharmacology & therapeutics · 2022Review
- Review
- Bilirubin as a Therapeutic Molecule: Challenges and Opportunities.Antioxidants (Basel, Switzerland) · 2021Review
- Review
- Peptide-Based Antiviral Drugs.Advances in experimental medicine and biology · 2021Article
- Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective.International immunopharmacology · 2021Review
- Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents.Arhiv za higijenu rada i toksikologiju · 2020Review
- Decarboxylative hydrazination of unactivated carboxylic acids by cerium photocatalysis.Chemical communications (Cambridge, England) · 2019Article
- A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair.Clinical pharmacology and therapeutics · 2018Observational
- Monomorphic ventricular tachycardia due to protease inhibitor intoxication by atazanavir.Clinical and experimental emergency medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atazanavir (Reyataz), a protease inhibitor (PI), is approved in many countries for use as a component of antiretroviral therapy (ART) regimens for the treatment of adult, and in some countries in paediatric, patients with HIV-1 infection. ART regimens containing ritonavir-boosted atazanavir improved virological and immunological markers in adult patients with HIV-1 infection, and had similar efficacy to regimens containing lopinavir/ritonavir in treatment-naive and treatment-experienced patients. In addition, unboosted atazanavir was noninferior to ritonavir-boosted atazanavir in treatment-naive patients. Atazanavir is administered once daily and has a low capsule burden. Atazanavir, whether unboosted or boosted, was generally well tolerated and appeared to be associated with less marked metabolic effects, including less alteration of lipid levels, than other PIs. These properties mean that boosted atazanavir, and unboosted atazanavir in patients unable to tolerate ritonavir, continues to have a role as a component of ART regimens in patients with HIV-1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.